Company Overview - NuoVance Biotechnology Co., Ltd. focuses on the research and development of functional proteins and high molecular organic materials, including enzymes, antigens, and antibodies [1] - The main products include biological reagents, diagnostic reagents, equipment, technical services, and consumables [1] Financial Performance - For Q1 2025, the company reported revenue of 285 million yuan, a year-on-year decrease of 5.50% [1] - The net profit for the same period was 1.91 million yuan, down 63.39% year-on-year [1] - The gross profit margin stood at 69.40% [1] Shareholder Information - As of March 31, 2025, the number of shareholders increased to 8,397, up by 671 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1] Market Valuation - The latest closing price of NuoVance is 21.34 yuan, reflecting a decline of 2.33% [1] - The company's price-to-earnings (P/E) ratio is significantly negative at -396.61, with a price-to-book (P/B) ratio of 2.18 and a total market capitalization of 8.488 billion yuan [2]

Group 1 - The core viewpoint of the news is that NuoVaxan's stock has shown a slight increase, with a closing price of 22.49 yuan, reflecting a 1.90% rise and a market capitalization of 8.945 billion yuan [1] - As of March 31, 2025, NuoVaxan has 8,397 shareholders, an increase of 671 from the previous period, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - NuoVaxan's main business focuses on the research and development of functional proteins and high molecular organic materials, with key products including biological reagents, diagnostic reagents, equipment, technical services, and consumables [1] Group 2 - In the latest quarterly report for Q1 2025, NuoVaxan reported a revenue of 285 million yuan, representing a year-on-year decrease of 5.50%, and a net profit of 1.9099 million yuan, down 63.39% year-on-year, with a gross profit margin of 69.40% [1] - The company's price-to-earnings (PE) ratio is significantly negative at -417.99 (TTM) and -494.37 (static), while the industry average PE is 48.90 (TTM) and 47.00 (static) [2] - The market valuation of NuoVaxan is 8.945 billion yuan, with a price-to-book ratio of 2.29, compared to the industry median of 2.40 [2]